UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 18, 2012
PAREXEL International Corporation |
(Exact name of registrant as specified in charter)
Massachusetts | 0-27058 | 04-2776269 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
195 West Street, Waltham, Massachusetts | 2,451 |
(Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code: (781) 487-9900
Not applicable. |
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations for the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 18, 2012, the Board of Directors of PAREXEL International Corporation (the “Company”) appointed Mark Goldberg to the position of President of the Company, effective as of July 1, 2012. Dr. Goldberg, who is 52, will continue to serve as the Company's Chief Operating Officer. Dr. Goldberg has served as Chief Operating Officer since July 2008. From June 2005 to July 2008, he was President, Clinical Research Services. From July 2000 to August 2008, he also served as President, Perceptive Informatics. From July 1999 to July 2000, Dr. Goldberg was a Senior Vice President in the Company's Clinical Research Services business and was responsible for managing the Advanced Technology and Informatics Group operating unit, which included IT applications support for both internal operations and external clients. Dr. Goldberg joined the Company as Vice President in 1997 at which time he established the Company's medical imaging group.
As a consequence of the appointment described above, Josef von Rickenbach will continue to serve as Chairman and Chief Executive Officer of the Company, but, effective as of July 1, 2012, will no longer hold the title of President of the Company. Mr. von Rickenbach had been serving as President since July 2005.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 20, 2012 | PAREXEL International Corporation |
By: | /s/ James F. Winschel, Jr. |
James F. Winschel, Jr. Senior Vice President and CFO | |